Economic evaluation of an adjunctive intraocular and peri-ocular steroid vitreoretinal surgery for open globe trauma: Cost-effectiveness of the ASCOT randomised controlled trial

• Published in: PloS one 2024-12, Vol.19 (12), p.e0311158
• Main Authors: Ezeofor, Victory 'Segun, Anthony, Bethany F, Bryning, Lucy, Casswell, Edward J, Cro, Suzie, Cornelius, Victoria R, Bunce, Catey, Robertson, Elizabeth, Kelly, Joanna, Murphy, Caroline, Banerjee, Philip J, Charteris, David G, Edwards, Rhiannon Tudor
• Format: Article
• Language: English
• Subjects: Acuity; Adult; Analysis; Biology and Life Sciences; Cost analysis; Cost benefit analysis; Cost effectiveness; Diabetes mellitus; Diabetic retinopathy; Economic analysis; Economic aspects; Economics; Evidence-based medicine; Eye; Eye injuries; Eye Injuries - economics; Eye Injuries - surgery; Eye surgery; Female; Hospitals; Humans; Injuries; Intervention; Investigations; Male; Medical research; Medicine and Health Sciences; Medicine, Experimental; Middle Aged; Parameter sensitivity; Parameter uncertainty; Patients; Quality of Life; Quality-Adjusted Life Years; Retinopathy; Sensitivity analysis; Social Sciences; Steroids; Surgery; Trauma; Uncertainty analysis; United Kingdom; Visual Acuity; Visual effects; Vitreoretinal Surgery - economics; Vitreoretinal Surgery - methods
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0311158

In the United Kingdom, it is estimated that 5,000 patients sustain eye injuries or ocular trauma requiring hospital admission annually, of which 250 patients will be permanently blinded. This study explores the cost-effectiveness of Adjunctive Steroid Combination in Ocular Trauma (ASCOT) given during surgery versus standard treatment in vitreoretinal surgery in patients with open globe trauma. This economic evaluation was embedded alongside the ASCOT RCT (ClinicalTrials.gov Identifier: NCT02873026). We conducted a primary cost-effectiveness analysis from a National Health Service perspective using the proportion of patients who achieved a visual acuity of 10 or more letter improvement on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale as the measure of effect, in developing incremental cost-effectiveness ratios (ICERs). Secondary cost-utility analysis using the EuroQol 5 Dimension 5 Level (EQ-5D-5L) to generate a cost per quality-adjusted life-year (QALY), and a cost-effectiveness analysis using vision-specific quality of life (QoL) was conducted. Sensitivity analyses were also applied to investigate parameter uncertainties. The sample size of the ASCOT intervention arm and standard care arm of this study was 130 and 129, respectively. The intervention cost per patient was estimated at £132. The proportion of participants with an ETDRS of 10 or more letter improvement was 0.47 for the ASCOT group with a mean cost of £5,526 per patient, while the standard care group had an effect of 0.43 with a mean cost of £5,099 per patient. The ICER value of the primary outcome was £12,178 per 10 or more letter improvement on the ETDRS score. The secondary result in terms of cost per QALYs gained had a probability of 44% being cost-effective at a willingness-to-pay threshold of £30,000/QALY gained. Though there is no formally accepted cost-effectiveness willingness-to-pay threshold for 10-letter or more improvement, the ASCOT intervention for open globe trauma is a low-cost intervention. The ASCOT intervention is not cost-effective when compared to the standard care in this group and setting. The proportion of patients in the ASCOT intervention arm with 10 or more letter improvement produced some positive results but this is outweighed by the costs.